A New Health Pact, But the Insurance Gap Stays

India Japan Kaizen — Health & Beauty Bridge Series, Part 4

Part 3 of this series closed on two open questions, both set up by Commerce Minister Piyush Goyal's own words at Sanjeevani 2026: would any insurer or health-tech company actually build the reimbursement and cashless products his 10-million-patient medical-value-travel target needs, and would a Japan-specific medical-travel service or a fresh Ayurveda-Kampo research tie appear in the weeks after. Five weeks on, the honest answer is a mix of real movement and a gap that's still exactly where Part 3 left it — plus one new document that matters more to the broader India-Japan health relationship than to medical tourism specifically.

The Insurance Gap Goyal Named Is Still Open

Start with what Goyal actually asked for: insurers and health-tech firms building products that make the international-patient journey seamless, with faster reimbursement and wider cashless coverage. The closest thing to a response came from Galaxy Health Insurance, which launched Galaxy Fly Global Travel Insurance on 21 August 2026, covering hospital costs, outpatient treatment, emergency medical evacuation, and repatriation for Indians travelling abroad for leisure, business, education, or work — with CEO G Srinivasan framing travel insurance as becoming "as essential as a passport." It's a real product launch from a real health insurer, in the same months Goyal was asking for exactly this kind of thing. But it covers the wrong direction: it protects Indians going out, not the foreign patients Goyal's plan needs to come in. None of India's larger standalone health insurers — Niva Bupa, ICICI Lombard, Care Health — has published a cashless product built specifically around an international patient arriving at an NABH-verified hospital. The scale of what's sitting unbuilt is worth naming: the Indian government's own May 2026 reckoning puts the global medical value travel market at roughly $115.6 billion in 2022, projected to reach roughly $286.1 billion by 2030. That's the opportunity an inbound-specific insurance product would be chasing, and as of this writing, nobody has launched one.

A Real Health Pact Lands — on a Different Track

Something did land on the government-to-government side, just not the side this series was watching. On 6 May 2026, India's Council of Medical Research (ICMR) and Department of Science & Technology (DST) signed a memorandum of cooperation with Japan's Agency for Medical Research and Development (AMED), during a bilateral meeting in New Delhi between Union Minister of State for Science & Technology Jitendra Singh and Japan's Minister of State for Science and Technology Policy Kimi Onoda. The scope is joint research, capacity building, and funding for health research and medical technologies, including internships in Japan for Indian researchers. It's the first formal, government-level India-Japan research agreement this series has found that sits squarely inside health — distinct from Part 2's Serum Institute vaccine-technology deal, which was a private commercial transfer, and distinct from the academic-to-academic tie Part 3 was waiting on between Japan's Kampo research institutions and an Indian counterpart. Notably, the ICMR-DST-AMED pact doesn't mention Ayurveda, Kampo, or traditional medicine anywhere in its scope — so it closes a different gap than the one Part 3 flagged, not that one.

Why Japan's Own Side Stays Thin

Part 3 noted that Japan's own inbound medical tourism is tiny — an estimated 20,000-30,000 foreign patients a year, against Thailand's roughly 3 million. A 2026 scoping review in the JMA Journal gives a concrete reason why Japan has stayed small rather than growing the way Thailand, Malaysia, or Singapore did: Japanese hospitals, emergency departments especially, carry real financial risk treating foreign patients, driven by language barriers, tourists travelling without private medical insurance, and short-term or undocumented residents falling outside Japan's public insurance system — with the review citing single facilities that have accumulated tens of millions of yen in unpaid bills. A separate 2025 study at one Tokyo tertiary hospital found that among uninsured, non-resident foreign inpatients admitted between January 2023 and February 2025, 5.9% left with outstanding bills at discharge. It's the mirror image of the gap Goyal is trying to close in India: just as India lacks an insurance product built for the foreign patient coming in, Japan's hospitals lack a systematic way to collect from one — which helps explain why Japan isn't building inbound capacity even as it eyes India as a potential source of outbound patients instead.

Checking the Rest of Part 3's List

A few quieter threads from Part 3 are worth a one-line update each, because the honest state of most of them is: unchanged.

• Shinon Healthcare — still the facilitator with the scale and the awards, still with no announced Japanese-language service tier.
• ICMG Partners and NirogStreet — the Japan-to-India wellness-product channel from 2023 appears to still be running at the same modest scale, with no expansion announced.
• Ayurveda-Kampo research — no new tie between the University of Toyama's Institute of Natural Medicine and an Indian institution has surfaced. The precedent for what that could look like already exists elsewhere in Japan's research system, though: the All India Institute of Ayurveda signed a formal academic MoU with Japan's National Institute of Advanced Industrial Science and Technology (AIST) back in 2022, for joint research and capacity-building in Ayurvedic medicine. Toyama doesn't need a new model — it needs the same kind of agreement AIST already found worth signing.

What's Still Missing

Line it up against Part 3's list and the shape hasn't changed, it's just gotten one data point more specific at every stop. The inbound insurance and health-tech product Goyal asked for in September still doesn't exist — the industry's energy this year went into outbound travel cover instead. The new ICMR-DST-AMED pact is real but is a research-funding instrument, not a patient-facing one, and says nothing about traditional medicine. Japan's own billing-risk data explains why no Japanese insurer or hospital group has reason to build inbound capacity unilaterally — somebody would need to build the cross-border insurance bridge first, for either direction. And the AIST-AIIA precedent sitting in Japan's own research system is the clearest evidence yet that a Toyama-India tie isn't a hard problem, just an unmade introduction.

If you work in cross-border health insurance, run an international-patient desk, or sit inside a Japanese research institute that already has a model for an India tie like AIST's — get in touch. This is precisely the kind of specific, already-proven connection India Japan Kaizen exists to make.

This is Part 4 of India Japan Kaizen's Health & Beauty Bridge Series, publishing weekly. Part 5 will check whether the ICMR-DST-AMED pact produces its first funded project or researcher placement, and whether Advantage Healthcare India's next edition or Sanjeevani's promised fourfold expansion finally brings the inbound insurance product this series keeps waiting for.